Company intelligence / Profile preview

Alcon Inc.

Ownership: Public · ALC
Employees: ~25599
Development stage: Commercial

Overview

Alcon has a commercial portfolio of surgical and vision care products. Their pharmaceutical pipeline includes Acoltremon (AR-15512), which has completed positive Phase 3 trials for dry eye disease with plans to file an NDA in mid-2024[6][10].

Therapeutic areas: Ophthalmology
Modalities: Ophthalmic pharmaceuticalssurgical devicescontact lensesintraocular lenses
Industry: Biotech

Drug pipeline

90 assets

olopatadine (Alcon Inc.)

Approved

89 more assets in the full pipeline.

Request access →

Financials

Market cap: $33.7B
Total revenue: $2.8B
Enterprise value: $37.6B

Beyond the preview

Go deeper on Alcon Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alcon Inc..

Explore the full profile